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Abstract
Objective: To evaluate poly(GP), a dipeptide repeat protein, and neurofilament
light chain (NfL) as biomarkers in presymptomatic C9orf72 repeat expansion
carriers and patients with C9orf72-associated frontotemporal dementia. Addi-
tionally, to investigate the relationship of poly(GP) with indicators of neurode-
generation as measured by NfL and grey matter volume. Methods: We
measured poly(GP) and NfL levels in cerebrospinal fluid (CSF) from 25
presymptomatic C9orf72 expansion carriers, 64 symptomatic expansion carriers
with dementia, and 12 noncarriers. We explored associations with grey matter
volumes using region of interest and voxel-wise analyses. Results: Poly(GP) was
present in C9orf72 expansion carriers and absent in noncarriers (specificity
100%, sensitivity 97%). Presymptomatic carriers had lower poly(GP) levels than
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symptomatic carriers. NfL levels were higher in symptomatic carriers than in
presymptomatic carriers and healthy noncarriers. NfL was highest in patients
with concomitant motor neuron disease, and correlated with disease severity
and survival. Associations between poly(GP) levels and small grey matter
regions emerged but did not survive multiple comparison correction, while
higher NfL levels were associated with atrophy in frontotemporoparietal cortices
and the thalamus. Interpretation: This study of C9orf72 expansion carriers
reveals that: (1) poly(GP) levels discriminate presymptomatic and symptomatic
expansion carriers from noncarriers, but are not associated with indicators of
neurodegeneration; and (2) NfL levels are associated with grey matter atrophy,
disease severity, and shorter survival. Together, poly(GP) and NfL show pro-
mise as complementary biomarkers for clinical trials for C9orf72-associated
frontotemporal dementia, with poly(GP) as a potential marker for target
engagement and NfL as a marker of disease activity and progression.
Introduction
Frontotemporal dementia (FTD) is a neurodegenerative
disorder characterized by early progressive behavioral
and/or language deficits.1,2 Up to 15% of patients with
FTD concomitantly develop motor neuron disease
(MND), and 10–20% of patients with MND develop
FTD,3 suggesting that the two disorders lie on a clinical
continuum. Pathogenic G4C2 repeat expansions in chro-
mosome 9 open reading frame 72 (C9orf72) are the most
common genetic cause of autosomal-dominant FTD and
amyotrophic lateral sclerosis (ALS).4,5 Potential pathome-
chanisms include the loss of function of normal C9orf72
protein, and/or toxicity resulting from the accumulation
of G4C2 transcripts that form RNA foci, interact with RNA-
binding proteins, and impair RNA processing.6 Expanded
G4C2 transcripts also lead to the production of five
dipeptide repeat (DPR) proteins through repeat-associated
non-ATG (RAN) translation.7,8 RAN translation of sense
transcripts of the repeat produces poly(GA), poly(GR), and
poly(GP), while RAN translation of antisense repeat tran-
scripts produces poly(PA), poly(PR), and poly(GP).
Although promising drugs for C9orf72 expansions have
emerged in preclinical studies, biomarkers for evaluating
their efficacy have not been adequately assessed in
humans. Disease-modifying therapies advancing toward
clinical trials include antisense oligonucleotides (ASOs)
and small molecules that target G4C2 transcripts and con-
sequently reduce G4C2 RNA foci and DPR proteins in
C9orf72 patient-derived cell models and animal models.9–13
In parallel with the rapid development of these potential
therapeutics, biomarkers that measure target engagement,
disease onset, and disease progression must be established
for clinical trials to be successful. Previous studies suggest
that poly(GP) is a promising marker of target engagement.
This protein is detectable in the cerebrospinal fluid (CSF)
of presymptomatic and symptomatic C9orf72 expansion
carriers,10,11,14 and poly(GP) levels in CSF from (G4C2)66-
expressing mice correlate with ASO-induced decreases in
G4C2 RNA expression, RNA foci burden, and DPR protein
levels within their brain.11 In addition, neurofilament light
chain (NfL) is a potential marker of disease severity and
progression for ALS, FTD, as well as other neurodegenera-
tive diseases, including Alzheimer’s disease.15–17 This marker
for axonal injury is also increased in symptomatic but not
presymptomatic C9orf72 expansion carriers, and correlates
with prognosis and disease severity in genetic FTD.18,19
Prior studies found that poly(GP) in CSF did not cor-
relate with indicators of disease progression or neurode-
generation, yet these studies were largely conducted in
patients with C9orf72-associated ALS.11,14,20 In addition,
no imaging data were available to assess potential rela-
tionships between CSF poly(GP) and grey matter atrophy.
In this study, we investigated the clinical correlates of
poly(GP) and NfL levels, and we explored associations
between these biomarkers and grey matter volume in a
large cohort of presymptomatic C9orf72 expansion carri-
ers and patients with C9orf72-associated dementia.
Materials and Methods
Subjects
We examined CSF from 101 subjects from C9orf72 fami-
lies, which was collected among eight sites (five sites par-
ticipating in the Genetic FTD Initiative (GENFI), the
University of California, San Francisco, the VU University
Medical Center, and IRCCS Fatebenefratelli; Table S1).
These CSF samples were obtained from 64 patients with
dementia caused by the C9orf72 repeat expansion (symp-
tomatic carriers), and 37 healthy first-degree family mem-
bers of C9orf72 expansion carriers. The unaffected family
members consisted of 25 presymptomatic C9orf72 expan-
sion carriers and 12 noncarriers, and clinical investigators
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were blinded to mutation status. Family members were
defined as unaffected if they had an absence of motor def-
icits, behavioral changes, and cognitive changes, as
assessed by neurological examination, neuropsychological
testing, and structured informant interviews (e.g., with a
spouse or sibling). The presence of a pathogenic C9orf72
repeat expansion, defined as more than 30 repeats,4 was
ascertained at the local sites. Symptomatic C9orf72 expan-
sion carriers were diagnosed according to criteria for
behavioral variant FTD (bvFTD, n = 47; 9 with concomi-
tant MND)1 or primary progressive aphasia (PPA, n = 6;
2 with concomitant MND)2 at time of inclusion. Subjects
with mild cognitive or behavioral symptoms who did not
meet these diagnostic criteria for FTD were classified as
having mild impairment (n = 9), and were included in
the symptomatic carrier group. Among these nine subjects
with mild symptomatology, seven had behavioral symp-
toms and two had memory symptoms. Lastly, two
patients had dementia with a predominant memory pre-
sentation, without known behavioral or motor changes.
ALS patients without cognitive or behavioral symptoms
were not included in this study because the number of
available subjects was too small to perform statistical
analyses on this subgroup (n = 2). Of the 101 subjects, 33
were included in our previous study on CSF NfL.18
Age at disease onset was defined as the age when care-
givers first noted a behavioral, motor, or cognitive
change, and disease duration was defined as the interval
between the age at disease onset and CSF collection.
Mini-Mental State Examination (MMSE) was used to
measure global cognition,21 and the Clinical Dementia
Rating scale (CDR) was used to assess symptom sever-
ity.22 All cognitive test scores were collected within
90 days of CSF collection.
Local ethics committees approved the study and all
participants (or their legal representative) provided writ-
ten informed consent.
CSF analyses
CSF was collected according to standardized local proce-
dures and longitudinal samples were available from 10
C9orf72 expansion carriers who remained in the same
clinical stage (presymptomatic or symptomatic) as when
the baseline CSF was collected. Measurements of
poly(GP) and NfL were performed blinded to clinical
information. We performed each biomarker measurement
in one laboratory to eliminate variability caused by testing
at multiple sites. Poly(GP) was measured at the Mayo
Clinic in Jacksonville, FL, and NfL was measured at the
VU University medical center. CSF poly(GP) concentra-
tions were measured in duplicate wells using a previously
described immunoassay.11
CSF NfL was measured in duplicate using the enzyme-
linked immunosorbent assay of Uman Diagnostics
(Umea, Sweden), according to the manufacturer’s instruc-
tions. Median intra- and interassay coefficient of varia-
tions were 1.5% (range: 0–11%) and 6.3% (range: 6.1–
16.7%), respectively. Two samples had NfL levels that
exceeded the upper limit of quantification of the assay
(10,000 pg/mL). Since there was insufficient CSF available
to measure NfL upon the dilution of these samples, they
were excluded from the NfL analyses. Among the longitu-
dinally collected samples, NfL measurements were not
performed on two because of insufficient CSF volumes.
For a given clinical subgroup (noncarriers, presymp-
tomatic carriers, and symptomatic carriers), CSF NfL and
poly(GP) levels did not significantly differ among the dif-
ferent centers at which CSF was collected.
MRI acquisition and preprocessing
T1-weighted MRI images (1,5 or 3 Tesla) captured
within 3 months of CSF collection were included for
imaging analyses (n = 72). After excluding poor quality
scans (e.g., motion artifact, n = 6) and scans from sub-
jects with structural abnormalities (including extensive
white matter hyperintensities or lacunar infarcts, n = 3),
scans were available for 63 subjects (11 noncarriers, 24
presymptomatic carriers, and 28 symptomatic carriers)
from 11 different scanners across seven sites. The NfL
level was unavailable for one symptomatic carrier. MRI
images were analyzed using two methods: region of
interest (ROI) analysis and voxel-based morphometry
(VBM). For ROI analysis, scans were parcellated into
brain regions as previously described,23 using an atlas
propagation and label fusion strategy,24 combining bilat-
eral ROIs to calculate grey matter cortical (frontal, tem-
poral, parietal, occipital, cingulate, insular), subcortical
(hippocampus, amygdala, caudate, putamen, thalamus),
and cerebellar volumes.25,26 Whole brain volumes were
calculated by combining all grey and white matter
regions extracted from the automated brain segmentation
method. All volumes were expressed as percentage of
total intracranial volume (TIV), computed with SPM12
(Statistical Parametric Mapping, Wellcome Trust Centre
for Neuroimaging, London, UK) running under Matlab
R2014b (Math Works, Natick, MA).27 For the VBM pre-
processing, T1 images were normalized using standard
spatial normalization in SPM12 (http://www.fil.ion.ucl.ac.
uk/spm/software/spm12/), modulated, corrected for non-
linear warping, then segmented into grey and white mat-
ter images. Grey matter images were smoothed using a
half-maximum isotropic Gaussian kernel with a size of
8 mm full-width chosen due to the heterogeneity of
scanners in the study.
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Statistical analysis
Statistical analyses were performed in SPSS 21.0 for Win-
dows (Armonk, NY) and graphs were drafted with
GraphPad Prism 7 (La Jolla, CA). Test statistics were con-
sidered significant at P < 0.05 (two-tailed). Since the
poly(GP) concentrations were non-normally distributed, a
log-transformation was applied after adding a constant of
0.1 to all values to avoid values of zero. CSF NfL was log-
transformed to normalize the data; three samples with
levels >10,000 pg/mL [all had concomitant MND with
either bvFTD (n = 2) or nonfluent variant PPA (n = 1)]
continued to skew the data and were therefore set at
10,000 pg/mL prior to the transformation to allow further
parametric analysis. Group comparisons of poly(GP) and
NfL were first performed by Kruskal–Wallis (with Dunn’s
post hoc tests) or Mann–Whitney tests on raw data, fol-
lowed by ANCOVAs on log-transformed data with cor-
rection for age and gender. When longitudinal CSF
samples were available, only the time-point close to MRI
or the first time point was used in group comparisons.
Area under the curve (AUC) with a 95% confidence
interval (CI), obtained by receiver operating characteristic
analyses, was used to examine diagnostic performance,
with optimal cut-off levels at the highest (sensitiv-
ity + specificity-1). Correlations with age at CSF collec-
tion, age at disease onset, disease duration, and cognitive
scores were assessed with Spearman correlations on non-
transformed data. Survival in patients was compared
among tertiles of poly(GP) and NfL by Kaplan–Meier
curves and Cox regressions adjusted for age, gender, pres-
ence of MND, and disease duration, with living patients
included as censored data. The Cox regressions were also
performed using poly(GP) or NfL as a continuous vari-
able. Although we had a relatively small number of carri-
ers with longitudinal samples (n = 10), exploratory
analyses on poly(GP) and NfL change were undertaken
by calculating the annual change [(second concentration–
first concentration)/interval between time points] and
testing these values against zero using a one-sample Wil-
coxon signed-rank test.
All imaging analyses were controlled for age at CSF col-
lection, gender, scanner, and TIV. Linear regressions were
used to explore the associations between transformed
poly(GP) or NfL and the ROIs. VBM analyses were con-
ducted in SPM12 using subjects’ smoothed, modulated
grey matter segments. Within SPM’s general linear model
framework, we used one-sample t-test designs in two sep-
arate analyses to correlate either log-transformed
poly(GP) levels or NfL with grey matter volume among
all C9orf72 expansion carriers. We repeated these correla-
tions between poly(GP) and NfL with grey matter in
presymptomatic and symptomatic expansion carrier
subgroups. Results were regarded as significant at
P < 0.05 family-wise error corrected for multiple compar-
isons (pfwe). When associations were not significant at this
threshold, a less stringent threshold of P < 0.001 was
used. Mean raw grey matter intensities were extracted
from regions showing significant results at P < 0.001
using the MARSBAR toolbox for SPM8,28 and plotted
against poly(GP) and NfL concentrations for visualization
purposes.
Results
Demographic and clinical data
In total, 64 symptomatic C9orf72 repeat expansion carri-
ers, 25 presymptomatic expansion carriers, and 12 healthy
noncarriers were included in our study (Table 1). The
clinical phenotypes of the symptomatic carriers were:
bvFTD (n = 38), bvFTD-MND (n = 9), subjects with
mild impairment (n = 9), PPA [n = 6; four nonfluent
variant PPA (two had concomitant MND), one with
semantic variant PPA, and one with logopenic variant
PPA], and dementia with a memory presentation (n = 2).
For presymptomatic carriers, the clinical diagnoses of
affected family members included: dementia only
(n = 16), dementia and/or MND (n = 8), or MND only
(n = 1). As expected, symptomatic carriers were older,
performed worse on the MMSE, and had higher CDR
sum of boxes (CDR-SB) scores compared to both noncar-
riers and presymptomatic carriers (Table 1). The median
age at disease onset in symptomatic carriers was 56 years
but varied widely (17–76 years). The median disease
duration at CSF collection was 2.8 years. Twenty-four
symptomatic carriers died during follow-up with a med-
ian survival of 2.1 years after CSF collection (IQR: 1.0–
4.2); the median follow-up interval of patients living at
follow-up was 2.8 years (IQR: 1.2–4.5).
Poly(GP) levels
C9orf72 expansion carriers had higher poly(GP) levels
than noncarriers (P < 0.001, Fig. 1A), which discrimi-
nated carriers from noncarriers with high accuracy (AUC
0.98, P < 0.001), with a specificity of 100%, and a sensi-
tivity of 96.6% (cut-off of >0.00 ng/mL, three expansion
carriers fell below this cut-off). Poly(GP) levels trended
higher in symptomatic carriers compared to presymp-
tomatic carriers (P = 0.10), and this observation became
statistically significant upon correction for age and gender
(post hoc Bonferroni corrected P = 0.04). Poly(GP) levels
did not differ between males and females, among
presymptomatic carriers grouped by their relatives’ diag-
noses, among clinical diagnoses of the symptomatic
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carriers, nor between patients with or without concomi-
tant MND (Fig. 1A and B). No significant associations
were found between poly(GP) and age at CSF collection,
age at disease onset, disease duration at time of CSF col-
lection, MMSE, CDR, or CDR-SB. No association
between poly(GP) and survival was found.
In our exploratory longitudinal analysis of 10 C9orf72
expansion carriers, a modest but significant increase in
poly(GP) was observed, and this was especially evident in
the four presymptomatic carriers (P = 0.03, Fig. 2A). The
median annual change in poly(GP) was 0.04 ng/mL, and
the median time between the first and second samples
was 2 years (range 1.0–5.4 years).
NfL levels
CSF NfL levels were significantly higher in symptomatic
carriers than in presymptomatic carriers and noncarriers
(both P < 0.001, Fig. 1C, Table 1), and did not differ
between the latter two groups. High CSF NfL levels differ-
entiated symptomatic from presymptomatic carriers with
a specificity of 96.0% and a sensitivity of 65.4% (cut-off
at 1169 pg/mL, AUC 0.89, P < 0.001). Patients with con-
comitant MND at the time of CSF collection had higher
NfL levels (median 5468 pg/mL) than those without con-
comitant MND (median 1819 pg/mL, P = 0.001, Fig. 1C
and D). NfL did not differ between males and females,
but did correlate with age in the total group and in each
subgroup (entire cohort rs = 0.60, P < 0.001, carriers
rs = 0.53, P < 0.001). NfL did not correlate with age at
onset or disease duration at CSF collection, but negatively
correlated with MMSE, and positively correlated with
CDR and CDR-SB in all carriers combined (MMSE
rs = 0.57, P < 0.001, CDR rs = 0.73, P < 0.001, CDR-SB
rs = 0.72, P < 0.001), and in symptomatic carriers after
stratification into presymptomatic versus symptomatic
stage (MMSE rs = 0.42, P = 0.01, CDR rs = 0.39,
P = 0.03, CDR-SB rs = 0.43, P = 0.03). High NfL levels
were associated with a poorer prognosis in terms of sur-
vival [Fig 3A, hazard ratio on NfL tertiles of 4.2 (95% CI:
2.0–8.6), P < 0.001].
NfL did not correlate with poly(GP) in all carriers
combined (P = 0.33, Fig. 3B), nor in presymptomatic or
symptomatic carriers separately (P = 0.58 and P = 0.85,
respectively). In an exploratory longitudinal analysis, NfL
levels increased over time in some individuals but
decreased in others, resulting in no significant longitudi-
nal change at the group level (P = 0.89, n = 8, Fig. 2B).
The different trajectories were not explained by evident
differences in clinical characteristics.
Imaging associations
Associations of poly(GP) with grey matter volume
Although none of the correlations between grey matter
volume and poly(GP) reached significance when corrected
for multiple comparisons, trends of interest were noted.
Table 1. Demographic, clinical, and biochemical characteristics of noncarriers, presymptomatic, and symptomatic C9orf72 repeat expansion
carriers.
Noncarriers, n = 12 Presymptomatic carriers, n = 25 Symptomatic carriers, n = 64 P-value
Male : female, n 7 : 5 8 : 17 35 : 29 0.13
Age at CSF collection, years (IQR) 44 (34–53) 47 (41–57) 60 (55–66)1 <0.001
Age at onset, years (range) n/a n/a 56 (17–76) n/a
Disease duration, years (range) n/a n/a 2.8 (0.5–28.9) n/a
Concomitant MND, n n/a n/a 11 n/a
MMSE (IQR) 30 (28–30) 29 (29–30) 25 (22–28)2 <0.001
CDR3 (IQR) 0 (0–0) 0 (0–0) 1 (0.5–1)1 <0.001
CDR–SB4 (IQR) 0 (0–0) 0 (0–0) 6 (3–8)1 <0.001
CSF Poly(GP), ng/mL (IQR) 0.00 (0.00–0.00) 0.75 (0.33–1.50)5 1.44 (0.49–2.51)5 <0.001
CSF NfL6, pg/mL (IQR) 333 (212–536) 429 (336–830) 1885 (848–2841)1 <0.001
MRI available, n 11 24 28 n/a
Medians are displayed for continuous variables, with according IQRs unless otherwise specified.
CSF, cerebrospinal fluid; IQR, interquartile range; MND, motor neuron disease; MRI, magnetic resonance imaging; n/a, not applicable; NfL, neuro-
filament light chain.
1Higher than noncarriers and presymptomatic C9orf72 expansion carriers.
2Lower than in noncarriers and presymptomatic C9orf72 expansion carriers.
3Available in 9 noncarriers, 18 presymptomatic C9orf72 expansion carriers and 32 symptomatic carriers.
4Available in 9 noncarriers, 18 presymptomatic and 28 symptomatic C9orf72 expansion carriers.
5Higher than in noncarriers.
6available in 12 noncarriers, 25 presymptomatic and 62 symptomatic C9orf72 repeat expansion carriers.
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Across all C9orf72 expansion carriers combined, higher
levels of poly(GP) trended with lower frontal and cingu-
late grey matter volumes from the ROI analysis (Table 2);
this trend remained after excluding FTD patients with
concomitant MND. The voxel-wise grey matter analysis
showed that poly(GP) tended to associate with regions of
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Figure 2. Longitudinal CSF poly(GP) and NfL levels. Longitudinal poly(GP) (A), but not NfL levels (B), increased significantly over time (P = 0.03
and P = 0.89, respectively) in presymptomatic (purple circles and connecting lines) and symptomatic (blue squares with connecting lines) C9orf72
repeat expansion carriers.
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Figure 3. NfL predicts survival, does not correlate with poly(GP), and negatively correlates with frontal cortical volume. (A) Kaplan–Meier curve
representing survival of symptomatic C9orf72 expansion carriers based on NfL levels; NfL levels were stratified into lowest (orange upper line),
middle (blue middle line), and highest (purple lower line) tertiles; vertical ticks represent living patients censored at the date the patient was last
known to be alive. Patients in the highest NfL tertile had the shortest survival. (B) NfL does not correlate with poly(GP) in presymptomatic (purple
circles) or symptomatic (blue squares) C9orf72 expansion carriers, and (C) higher NfL levels significantly associated with lower frontal cortical
volumes across presymptomatic (purple circles) and symptomatic (blue squares) C9orf72 expansion carriers combined (ROI analysis).
Figure 1. Poly(GP) and NfL levels by clinical stage and diagnosis. (A) Poly(GP) levels were higher in presymptomatic and symptomatic C9orf72
expansion carriers than in healthy noncarriers, and higher in symptomatic carriers than in presymptomatic carriers after correction for age and
gender. (B) Poly(GP) levels did not differ between different diagnoses. (C) NfL levels were elevated in symptomatic C9orf72 repeat expansion
carriers when compared to noncarriers and presymptomatic carriers. (D) NfL levels were highest in symptomatic carriers with concomitant MND.
Patients with concomitant MND at CSF collection are displayed as orange filled squares, those who developed MND after collection are displayed
as blue filled triangles. Horizontal lines represent group medians. P-values from the ANCOVA analyses are displayed (corrected for age and
gender) as follows: *P ≤ 0.05; **P ≤ 0.01; ***P ≤ 0.001; ns: not significant.
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bilateral dorsomedial prefrontal and medial frontal cor-
tices and lateral temporal cortex at P < 0.001 (Fig 4A,
Table S2). Within these grey matter regions, bvFTD-MND
and bvFTD showed the lowest grey matter intensities
(Fig 4B). For the presymptomatic carriers, higher poly(GP)
levels tended to associate with lower temporal ROI volume
(Table 2), and lower volume in medial prefrontal cortex
and scattered regions within lateral temporal cortices in the
VBM analysis (P < 0.001, Fig 4C, Table S2). For symp-
tomatic carriers, higher poly(GP) levels trended with lower
cingulate grey matter ROI volume (Table 2), and with
lower volume in a small dorsomedial frontal cluster in the
VBM analysis (P < 0.001, Fig 4D).
Associations of NfL levels with grey matter volume
Higher CSF NfL levels were associated with lower frontal
(Fig. 3C), temporal, and parietal ROI grey matter
volumes in all carriers combined, but the latter two ROIs
did not survive multiple comparisons correction
(Table 2). In the VBM analysis, higher NFL levels were
associated with lower grey matter volumes in the ventral
and dorsomedial prefrontal cortex, ventral and dorsal
insula, anterior cingulate, caudate, medial thalamus, and
several other frontotemporoparietal regions (P < 0.001,
Fig 5A and B, Table S2). At pfwe < 0.05, higher NfL levels
were associated with lower grey matter volume in small
regions of dorsolateral prefrontal cortex, dorsal posterior
insula, and the left caudate. In a subgroup analysis of
presymptomatic carriers only, no significant correlations
between grey matter ROIs and NfL emerged, and voxel-
wise, NfL levels correlated with grey matter deficits in the
inferior and middle frontal gyrus, pre- and postcentral
gyrus, operculum, superior temporal gyrus, lateral parietal
regions, and the caudate only at P < 0.001 (Fig 5C,
Table S2) with no significant regions at pfwe < 0.05. For
Table 2. Associations between poly(GP) or NfL and grey matter regions of interest in C9orf72 expansion carriers.
ROI
poly(GP) NfL
All carriers,
n = 52
Presymptomatic
carriers,
n = 24
Symptomatic carriers,
n = 28
All carriers,
n = 51
Presymptomatic
carriers, n = 24
Symptomatic
carriers, n = 27
Whole brain b 0.11 0.22 0.09 0.19 0.22 0.38
P 0.52 0.35 0.73 0.41 0.54 0.21
Frontal b 0.25 0.35 0.17 0.60 0.28 0.70
P 0.045 0.10 0.48 <0.0011 0.38 <0.0011
Temporal b 0.20 0.49 0.02 0.42 0.45 0.19
P 0.12 0.02 0.92 0.01 0.17 0.43
Parietal b 0.16 0.08 0.06 0.43 0.40 0.35
P 0.24 0.69 0.78 0.01 0.17 0.12
Occipital b 0.19 0.07 0.18 0.32 0.06 0.34
P 0.19 0.73 0.38 0.09 0.84 0.14
Cingulate b 0.31 0.05 0.51 0.07 0.04 0.07
P 0.02 0.81 0.02 0.69 0.88 0.79
Insula b 0.01 0.07 0.09 0.15 0.02 0.13
P 0.97 0.76 0.63 0.31 0.94 0.53
Cerebellum b 0.19 0.31 0.01 0.04 0.36 0.32
P 0.24 0.19 0.98 0.87 0.30 0.26
Hippocampus b 0.02 0.23 0.01 0.03 0.10 0.05
P 0.87 0.35 0.97 0.97 0.80 0.83
Amygdala b 0.23 0.24 0.88 0.35 0.10 0.32
P 0.15 0.29 0.39 0.10 0.77 0.28
Caudate nuclei b 0.25 0.35 0.23 0.10 0.21 0.27
P 0.07 0.05 0.30 0.62 0.45 0.30
Putamen b 0.24 0.12 0.31 0.33 0.27 0.41
P 0.06 0.62 0.11 0.05 0.53 0.06
Thalamus b 0.08 0.09 0.16 0.02 0.05 0.07
P 0.52 0.68 0.49 0.91 0.89 0.95
Associations between poly(GP) (first three columns) and NfL (last three columns) concentrations and different brain and grey matter ROIs in
C9orf72 repeat expansion carriers, by means of linear regression corrected for age, gender, and scanner. P-values below 0.05 are bolded. NfL,
neurofilament light chain; ROI, region of interest.
1Significant after correction for multiple testing (Bonferroni corrected P-value: P < 0.004).
590 ª 2018 The Authors. Annals of Clinical and Translational Neurology published by Wiley Periodicals, Inc on behalf of American Neurological Association.
Poly(GP) and Neurofilament in C9orf72-FTD L.H.H. Meeter et al.
symptomatic carriers, NfL significantly correlated with
frontal cortex in the ROI analysis, and the VBM showed
associations with bilateral dorsolateral prefrontal cortex,
anterior and mid cingulate cortex, dorsal insula, pre- and
postcentral gyrus, medial parietal regions and the caudate
(P < 0.001, Fig 5D), with no significant regions at
pfwe < 0.05.
Discussion
In this study, CSF poly(GP), NfL, and grey matter vol-
umes were determined in a cohort of 89 C9orf72 repeat
expansion carriers to examine associations among these
measures. Poly(GP) was detected in CSF of both
presymptomatic and symptomatic C9orf72 expansion car-
riers, and not detected in noncarriers. In contrast, we
found high NfL levels exclusively in symptomatic carriers,
while levels in presymptomatic carriers remained similar
to healthy noncarriers. Higher NfL levels correlated with
greater disease severity as well as shorter survival. In addi-
tion, higher NfL levels associated with lower grey matter
volumes in regions known to show smaller grey matter
volume in presymptomatic and symptomatic carriers, but
for poly(GP), only trends were observed. As such, CSF
NfL and poly(GP) capture abnormalities during different
phases of the disease, and may thus serve as
Figure 4. Voxel-wise associations of grey matter deficits with higher poly(GP) levels. (A) Cross-sectionally, regions in bilateral dorsolateral
prefrontal and medial frontal cortices, and lateral temporal cortex showed lower grey matter volume associated with higher poly(GP) levels in the
voxel-wise analysis of C9orf72 repeat expansion carriers. Significant clusters were defined at a t-threshold of P < 0.001 uncorrected, no significant
clusters were found at pfwe < 0.05. Color bars represent t-scores, and statistical maps are superimposed on the Montreal Neurological Institute
template brain. The left side of the axial and coronal images corresponds to the left (L) side of the brain. (B) Mean grey matter intensity versus
log-transformed poly(GP) within the P < 0.001 map in (A), for 24 presymptomatic C9orf72 expansion carriers (grey dots), 4 mild impairment
(orange dots), 17 bvFTD (pink dots), 5 bvFTD-MND (green dots), and 1 PPA (purple dot) plotted for visualization purposes only. In general, FTD-
MND showed the lowest grey matter intensities compared to the other diagnostic groups. (C) For presymptomatic carriers, grey matter volume
was negatively correlated with poly(GP) in medial prefrontal cortex and scattered regions within lateral temporal cortices. (D) For symptomatic
carriers, a small dorsomedial frontal cluster showed lower grey matter volume associated with higher poly(GP) levels.
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complementary biomarkers for disease detection and
future treatment monitoring.
Poly(GP) is a highly sensitive and specific
biomarker for C9orf72 expansion carriers
We showed that CSF poly(GP) has high power to differ-
entiate C9orf72 expansion carriers and noncarriers, consis-
tent with previous reports.10,11,14 Interestingly, poly(GP)
levels were undetectable in three C9orf72 expansion carri-
ers, who had various clinical presentations, including a
presymptomatic individual, a bvFTD patient, and a PPA
patient. Future studies may inform whether alternative
detection strategies with increased sensitivity would detect
poly(GP) in these individuals, or whether their poly(GP)
levels are truly negligible. Should postmortem tissue
become available for these individuals and others, it
would be of particular interest to evaluate how CSF
poly(GP) levels compare to the frequency of DPR pro-
tein pathology and levels of repeat-containing transcripts
in the brain. As in previous studies,11,14 we found that
poly(GP) was detectable in CSF from presymptomatic
C9orf72 expansion carriers, suggesting that DPR protein
production emerges prior to neurodegeneration and that
poly(GP) can be actively released from putatively healthy
neurons. This notion is supported by in vitro experi-
ments that show that DPR proteins are secreted from
cultured cells.11,29 Reports of autopsy studies in C9orf72-
patients have also described widespread DPR protein
pathology prior to the formation of TDP-43 inclusions
Figure 5. Voxel-wise associations of grey matter deficits with higher NfL levels. (A) Widespread regions including ventral and dorsomedial
prefrontal cortex, ventral and dorsal insula, anterior cingulate, caudate, and medial thalamus showed lower grey matter volume (voxel-wise
analysis) associated with higher NfL levels. Significant clusters were defined at a t-threshold of P < 0.001 uncorrected (blue-green colored) and
pfwe < 0.05 (red colored). Color bars represent t-scores, and statistical maps are superimposed on the Montreal Neurological Institute template
brain. The left side of the axial and coronal images corresponds to the left (L) side of the brain. (B) Mean grey matter intensity versus log-
transformed NfL levels within the P < 0.001 map in (A), for 24 presymptomatic C9orf72 expansion carriers (grey dots), 4 mild impairment (orange
dots), 17 bvFTD (pink dots), 4 bvFTD-MND (green dots), and 1 PPA (purple dot) plotted for visualization purposes only. Both presymptomatic (C)
and symptomatic carriers (D) show associations of NfL with grey matter atrophy in bilateral dorsolateral prefrontal cortex, parietal regions, and
caudate. Symptomatic carriers (D) additionally show grey matter atrophy associated with NfL in key hubs targeted in bvFTD, including anterior
and mid cingulate cortex and insula.
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and neuronal loss.30–32 These studies provide converging
evidence that poly(GP) expression arises early in the
lifespan of C9orf72 expansion carriers.
Poly(GP) levels are higher in symptomatic
C9orf72 expansion carriers compared to
presymptomatic carriers
Symptomatic carriers had higher poly(GP) levels compared
to presymptomatic carriers after correcting for age and
gender. In parallel, we found a modest increase in CSF
poly(GP) over time in a small subset of 10 C9orf72 expan-
sion carriers, most frequently in the presymptomatic
subjects. In contrast, other studies had not identified a
significant difference in poly(GP) levels between presymp-
tomatic and symptomatic carriers,11,14 nor an increase in
poly(GP) levels over time.11 The time interval between
repeated CSF collections was longer in the present explora-
tory analysis, suggesting that changes in poly(GP) might
only emerge over longer periods. Measuring poly(GP) in
larger cohorts over extended time periods as individuals con-
vert from the presymptomatic to symptomatic phase will
further help elucidate the temporal trajectory of poly(GP),
and whether levels change relative to symptom onset.
We found that poly(GP) levels did not differ among
clinical phenotypes, and did not correlate with age at dis-
ease onset or survival. Although there is a possibility of a
type II error (i.e., a false-negative association) given that
several clinical subgroups had a small sample size, these
data are in line with the lack of associations between clini-
cal phenotypes and other C9orf72-associated features, such
as repeat size and RNA foci burden.33,34 While we were
unable to examine correlations between CSF poly(GP) and
repeat length in blood because repeat length data were not
available, such an analysis would likely be complicated
given the substantial variation in repeat sizes among vari-
ous tissues from the same individual.33 Furthermore, a pre-
vious study has shown no association between CSF
poly(GP) and repeat length in blood,14 and we observed no
association between poly(GP) levels in the cerebellum or
frontal cortex and repeat length in these regions.35
Nonetheless, examining associations between antemortem
CSF poly(GP) and repeat size, poly(GP) levels, and levels
of other DPR proteins in various neuroanatomical regions
will be of interest when postmortem tissue becomes
available from a suitable number of cases. Also, as argi-
nine-containing DPR proteins, poly(GR) and poly(PR), are
considered to be highly toxic,6 it is possible that elevated
levels of these DPR proteins may correlate with clinical fea-
tures and measures of neurodegeneration. The develop-
ment of immunoassays quantifying these proteins remains
technically challenging, but may lead to more insights into
C9orf72 disease mechanisms.
NfL is normal in presymptomatic C9orf72
expansion carriers and is elevated in
symptomatic carriers
Determining symptom onset in C9orf72 repeat expansion
carriers is notoriously challenging. Presymptomatic carri-
ers have a high incidence of psychiatric symptoms over-
lapping with bvFTD symptomatology,36 and some carriers
have a mild, slowly progressive prodromal phase spanning
several decades.37 Consequently, surrogate endpoints
reflecting neurodegeneration are critical for assessing dis-
ease onset and the efficacy of therapeutic interventions.
Our data show that NfL is elevated during the symp-
tomatic phase of C9orf72-associated dementia and corre-
late with indicators of disease severity (i.e., MMSE, CDR,
and CDR-SB), survival, and grey matter atrophy, consis-
tent with other studies of NfL in sporadic and genetic
FTD.18,38,39 In mouse models, NfL also correlates with
disease severity, specifically with the burden of a-synu-
clein, tau, or b-amyloid inclusions, and NfL levels are
attenuated with treatment.40 Thus, NfL could be utilized
in clinical trials to stratify patients into more homoge-
neous groups with respect to disease severity and to assess
the neuroprotective effect of therapeutic interventions.
Furthermore, the strong association between CSF NfL and
survival supports the use of NfL as a prognostic marker.
NfL can now be reliably measured in serum and plasma,
which is collected less invasively than CSF, making it
promising for clinical use, especially when frequent mea-
sures are needed.17,18,41
Our small longitudinal study of CSF NfL levels did not
show consistent changes over the time intervals assessed.
Previous studies on ALS patients reported stable NfL
levels, but showed an increase over time for a subset of
patients with a rapid disease progression.17,42,43 Serum
NfL levels have also been shown to progressively increase
in sporadic PPA patients.44 The discrepancy between our
and previous findings could be attributable to the small
size of our longitudinal cohort, and the range of clinical
phenotypes and disease durations among individuals at
the time of sample collection. Given that the rate of neu-
rodegeneration can differ not only throughout the course
of disease but also among patients, additional longitudinal
studies on larger cohorts of C9orf72 expansion carriers
are needed to fully understand the temporal trajectory of
NfL in relation to clinical changes.
Relationships between poly(GP) and
indicators of neurodegeneration
This study did not show a significant relationship between
poly(GP) levels and indicators of neurodegeneration, as
reflected by NfL levels and grey matter volumes. Similarly,
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previous studies show no correlation between poly(GP)
and NfL,14 nor neurofilament heavy chain (a different
neurofilament subunit) in C9orf72-associated ALS.20
Because previous studies have shown lower grey matter
volumes in both presymptomatic and symptomatic carri-
ers compared to controls,23,36,45,46 we had hypothesized
that higher levels of poly(GP) might be associated with
lower grey matter volumes in C9orf72-targeted regions.
We found a trend toward higher poly(GP) with lower
frontal and cingulate volume in our ROI analysis. In par-
allel with the ROI analysis, the voxel-wise analysis showed
that certain sparse regions of lower grey matter volumes
tended to associate with higher poly(GP), which included
regions in the bilateral dorsolateral prefrontal, medial
frontal, and lateral temporal cortices. Although higher
poly(GP) levels showed a relatively weak association with
lower grey matter volumes in our analyses, the regions
identified include those atrophied in C9orf72-associated
FTD patients,45,47–49 and show reduced volume in
presymptomatic C9orf72 expansion carriers.23,36
Interestingly, our subgroup analysis of presymptomatic
carriers showed a trend for association between higher
poly(GP) and reduced bilateral medial orbitofrontal cor-
tex, but symptomatic carriers showed only sparse regions
that trended toward an association with high poly(GP).
One potential explanation for this result is that DPR
accumulation may arise focally during the presymp-
tomatic phase and become widespread during the symp-
tomatic phase, thus attenuating any potential relationship
between grey matter atrophy and poly(GP) during the
symptomatic phase. Overall, our results suggest that
higher poly(GP) levels may be associated with some key
foci in C9orf72-associated regions, particularly for
presymptomatic carriers, but poly(GP) levels are not a
marker for neurodegeneration per se.
Higher NfL levels are associated with grey
matter deficits
Elevated NfL levels were associated with lower grey matter
volume based on both types of analysis. These data reveal
vulnerable neuroanatomical structures during the
presymptomatic and symptomatic stages, which include
ventral and dorsomedial prefrontal cortex, ventral and
dorsal insula, anterior cingulate, caudate, and the medial
thalamus. These regions are highly anatomically congru-
ent with atrophy patterns found in C9orf72-associated
frontotemporal dementia.45,47–50 Notably, several studies
confirmed that the medial thalamus is a region affected
across C9orf72 expansion carriers,50 even during the
presymptomatic phase.23,36,46 Interestingly, our subgroup
analysis of presymptomatic carriers showed that higher
NfL levels were associated with smaller bilateral
frontoparietal and caudate volumes, which may indicate
that these regions are among the earliest regions of neu-
rodegeneration, but longitudinal presymptomatic studies
are needed to test this hypothesis.
Conclusion
The strength of this study is the use of a multimodal
approach combining two CSF biomarkers with quantita-
tive structural imaging metrics to investigate the relation-
ship between poly(GP) and indicators of
neurodegeneration in a large cohort of presymptomatic
and symptomatic C9orf72 expansion carriers. To the best
of our knowledge, this is the largest study thus far on
poly(GP) in C9orf72-associated FTD, and the first in
examining associations between DPR protein levels and
grey matter volume. We used two neuroimaging methods:
ROI analyses, the metrics of which are reliable and can be
readily analyzed by clinical groups, and voxel-wise analy-
ses, which can refine grey matter deficits in a more granu-
lar fashion. We show that poly(GP) and NfL are
promising complementary biomarkers that capture the
effects of the C9orf72 repeat expansion during different
phases, and demonstrate different relationships with grey
matter volume. While poly(GP) may display less utility as
a prognostic or staging biomarker, it shows great promise
as a pharmacodynamic biomarker for therapeutic
approaches that target G4C2 RNA in preclinical models.
11
Importantly, poly(GP) levels are detectable in presymp-
tomatic carriers and would thus make the inclusion of
this population in clinical trials more feasible. Because
NfL reflects neurodegeneration and is associated with grey
matter atrophy, it will be most useful for monitoring
disease severity, and predicting disease progression and
survival.
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